Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Pr…
An institutional-grade, numbers-driven thesis on ABT — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 7, 2026, TradersQuant's model rates Abbott Laboratories (ABT) 59/100 with a 12-month base-case forecast of $123.00 — +13.9% versus the current price of $107.95. Abbott Laboratories trades at $107.95 in the Healthcare sector, with a market capitalisation of $186.79B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for ABT is $123.00, implying +13.9% versus the current price. The model's 12-month scenario range runs from $83.52 (bear) to $107.43 (bull), with a base case of $91.87.
On the fundamentals, Abbott Laboratories shows a P/E of 34.7, trailing revenue of $44.33B, revenue growth of +5.7% YoY, a dividend yield of 2.30%. This page also tracks ABT's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ABT currently carries a TradersQuant composite score of 59/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $123.00 implies +13.9% from $107.95. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for ABT is $123.00, about +13.9% versus the latest price of $107.95. Consensus is based on 41 analysts.
TradersQuant's 12-month model forecast for ABT is a base case of $91.87, ranging from $83.52 (bear) to $107.43 (bull), an expected return of -14.9%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ABT over the next 12 months is $91.87 in the base case (bear $83.52, bull $107.43), versus today's price of $107.95. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ABT — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ABT's fair value at $123.00, implying +13.9% of expected upside versus the current price.
Yes — Abbott Laboratories pays a dividend yielding 2.30% (about $2.48 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
